Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
The Lancet ( IF 168.9 ) Pub Date : 2017-12-01 , DOI: 10.1016/s1470-2045(17)30691-5
Heather A Wakelee ₁ , Suzanne E Dahlberg ₂ , Steven M Keller ₃ , William J Tester ₄ , David R Gandara ₅ , Stephen L Graziano ₆ , Alex A Adjei ₇ , Natasha B Leighl ₈ , Seena C Aisner ₉ , Jan M Rothman ₁₀ , Jyoti D Patel ₁₁ , Mark D Sborov ₁₂ , Sean R McDermott ₁₃ , Roman Perez-Soler ₁₄ , Anne M Traynor ₁₅ , Charles Butts ₁₆ , Tracey Evans ₁₇ , Atif Shafqat ₁₈ , Andrew E Chapman ₁₉ , Samer S Kasbari ₂₀ , Leora Horn ₂₁ , Suresh S Ramalingam ₂₂ , Joan H Schiller ₂₃ ,

Affiliation

Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Dana-Farber Cancer Institute and Harvard T H Chan School of Public Health, Boston, MA, USA.
Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, USA.
Albert Einstein Medical Center, Philadelphia, PA, USA.
UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Division of Medical Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Princess Margaret Cancer Centre, Toronto, ON, Canada.
Rutgers New Jersey Medical School and Cancer Institute of New Jersey, Newark, NJ, USA.
The Regional Cancer Center, Erie, PA, USA.
Department of Medicine (Oncology), Northwestern University, Chicago, IL, USA.
Edina Clinic, Edina, MN, USA.
Department of Medical Oncology, Tallaght University Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland.
Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.
Department of Medicine (Oncology), University of Wisconsin, Madison, WI, USA.
Division of Oncology, University of Alberta, Edmonton, AB, Canada.
Department of Medicine (Oncology), University of Pennsylvania, Philadelphia, PA, USA.
Heartland Cancer Research NCORP and Missouri Baptist Cancer Center, St Louis, MO, USA.
Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC, USA.
Department of Medicine (Oncology), Vanderbilt University Medical Center, Nashville, TN, USA.
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Division of Hematology/Oncology, University of Texas Southwestern, Dallas, TX, USA.

Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.

中文翻译：

已切除的非小细胞肺癌患者联合或不联合贝伐珠单抗的辅助化疗 (E1505)：一项开放标签、多中心、随机、3 期试验。

对切除的早期非小细胞肺癌（NSCLC）进行辅助化疗可提供适度的生存获益。贝伐单抗是一种针对 VEGF 的单克隆抗体，添加到晚期非鳞状 NSCLC 的铂类化疗中可改善预后。我们的目的是评估在早期切除的非小细胞肺癌的辅助化疗中添加贝伐珠单抗。

更新日期：2017-11-30

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>